中华皮肤科杂志 ›› 2009, Vol. 42 ›› Issue (1): 12-15.

• 论著 • 上一篇    下一篇

辛伐他汀对硬皮病小鼠模型的影响

刘彤云 王千秋 钱革 其木格 陶小华 齐淑贞   

  1. 南京市医科院皮研所
  • 收稿日期:2008-02-14 修回日期:2008-03-07 出版日期:2009-01-15 发布日期:2009-01-15
  • 通讯作者: 刘彤云 E-mail:tongyun731@yahoo.com.cn

Effects of simvastatin on the mouse model of sclerotic skin

  • Received:2008-02-14 Revised:2008-03-07 Online:2009-01-15 Published:2009-01-15

摘要:

目的 探讨辛伐他汀对硬皮病小鼠模型胶原合成的影响。方法 采用博来霉素诱导的动物模型,分早期给药组和硬化后给药组。用5 mg·kg-1·d-1辛伐他汀处理,用药4周后收集标本,采用HE染色观察皮损组织病理改变并测量表真皮厚度,比色法检测皮损羟脯氨酸含量,并利用逆转录-聚合酶链反应(RT-PCR)方法检测小鼠硬皮病皮损前胶原(pro-COL1α1) mRNA的表达情况。结果 早期给药组中,模型组与阴性对照组比较,小鼠真皮内胶原增粗,表真皮厚度和羟脯氨酸含量及pro-COL1α1 mRNA 表达明显增加(P < 0.01);而5 mg·kg-1·d-1辛伐他汀处理组较模型组小鼠真皮厚度变薄(P < 0.05),羟脯氨酸含量降低(P < 0.01),皮损pro-COL1α1 mRNA表达下降(P < 0.05)。硬化后给药组中,辛伐他汀处理组与空白对照组比较小鼠真皮厚度、羟脯氨酸含量均无明显改善,但pro-COL1α1 mRNA表达下降(P < 0.05)。结论 早期予以辛伐他汀处理可以减轻博来霉素诱导的小鼠皮肤硬化程度。硬化后予以辛伐他汀处理则皮肤硬化改善不明显。

关键词: 硬皮病;小鼠;动物模型;辛伐他汀

Abstract:

Objective To study the effect of simvastatin on the mouse model of sclerotic skin. Methods A total of 44 mice were divided into two groups, i.e., early administration group (n = 24) and post-induction administration group (n = 20), and the former was classified into three subgroups, including negative group, model group and simvastatin-treated group, and the latter into two groups, namely blank control group, simvastatin-treated group. The mouse model of sclerotic skin was established by local injections of bleomycin in the back of BALB/c mice. Simvastatin was administered by gavage at a dose of 5 μg per kilogram body weight per day for 4 weeks to mice at the same time when bleomycin was injected in the early group or after 4-week bleomycin injection in the post-induction group. Skin sections were prepared 24 hours after the last administration of simvastatin for histopathological examination and measurement of dermal thickness with HE staining, determination of hydroxyproline content via colorimetry, and mRNA expression of procollagen α1 (Ⅰ) by RT-PCR. Results In the early administration group, a significant increment was observed in the diameter of dermal collagen, skin thickness, and hydroxyproline content in model group compared with the negative control group (all P < 0.01), whereas decreased dermal thickness, hydroxyproline content and mRNA expression of procollagen α1 (Ⅰ) were noticed in simvastatin-treated group in comparison with the model group (P < 0.05, 0.01 and 0.05, respectively). No obvious improvement was achieved in dermal thickness or hydroxyproline content in simvastatin-treated group compared with blank control group (both P > 0.05), but the mRNA expression of procollagen α1 (Ⅰ) was inhibited in the former group (P < 0.05). Conclusion Skin sclerosis is relieved significantly by administration of simvastatin at the induction of sclerosis but not by that after the induction of sclerotic skin.

Key words: scleroderma ,systemic;Simvastatin;Model, animal;Bleomycin